Vialwirebiotech, curated
July 2, 2026, 5:15 PM
June 18, 2026
- 4:25 PM · BioPharma Dive4:25 PMModerna flu vaccine wins unanimous support from FDA panel — BioPharma Dive
- 3:56 PM · STAT News
- 12:00 PM · BioWorld12:00 PMBiopharma IPOs stay strong as Kardigan prices upsized $400M offering — BioWorld
- 12:00 PM · BioWorld12:00 PMF2G preps NDA for first new antifungal in 20 years on solid phase III — BioWorld
- 12:00 PM · BioWorld12:00 PMGSK-Spero’s oral antibiotic Utebzi for cUTI wins US FDA nod — BioWorld
- 11:45 AM · BioPharma Dive11:45 AMcAMPfield lands $180M to build gut disease drug — BioPharma Dive
- 10:18 AM · Pharmaceutical Executive10:18 AM<![CDATA[FDA Approves Additional Indication for Capvaxive in Children Aged 2-17 at Increased Risk for Pneumococcal Disease ]]> — Pharmaceutical Executive
- 9:00 AM · BioWorld9:00 AMAlturos Therapeutics advances ALT-0135 into IND-enabling studies — BioWorld
- 9:00 AM · BioWorld9:00 AMSaniona reports preclinical data for SAN-2668 — BioWorld
- 9:00 AM · BioWorld9:00 AMFDA clears IND for Cenna’s 8M2D for Alzheimer’s disease — BioWorld
- 9:00 AM · BioWorld9:00 AMCEPI extends support for Abera’s vaccine platform — BioWorld
- 9:00 AM · BioWorld9:00 AMBeam Therapeutics’ BEAM-304 gains IND clearance for PKU — BioWorld
- 9:00 AM · BioWorld9:00 AMANT-activating uncoupler RV-202 drives selective fat loss in obese mice — BioWorld
- 6:40 AM · Pharmaceutical Technology6:40 AMADA26: retatrutide delivers unprecedented weight loss in Phase III TRIUMPH-1 — Pharmaceutical Technology
- 5:04 AM · Pharmaceutical Technology5:04 AMLG AI Research and D&D Pharmatech sign agreement for oral peptide drugs — Pharmaceutical Technology
June 17, 2026
- 12:11 PM · Bloomberg — Technology12:11 PMBioNTech Investor Förtsch Says Founders’ Spinout Raises Concerns — Bloomberg — Technology
- 12:00 PM · Drug Discovery World12:00 PMTherapy enables 89% survival rate in myeloma patients — Drug Discovery World
- 12:00 PM · BioWorld12:00 PMSpyre’s Skyline-UC double win lifts hopes for IBD antibody combos — BioWorld
- 12:00 PM · BioWorld12:00 PMHMNC raises $50M series B to prep depression drugs for phase III — BioWorld
- 12:00 PM · BioWorld12:00 PMRx tariff just around the corner — BioWorld
- 11:30 AM · Drug Discovery World11:30 AMUlcerative colitis treatment shows best-in-class potential — Drug Discovery World
- 11:09 AM · BioPharma Dive11:09 AMJazz zeroes in on next-gen T cell engagers with AbCellera deal — BioPharma Dive
- 9:00 AM · BioWorld9:00 AMVedana Therapeutics launches with focus on migraine — BioWorld
- 9:00 AM · BioWorld9:00 AMAcumen selects development candidates for Alzheimer’s disease — BioWorld
- 9:00 AM · BioWorld9:00 AMCalidi receives pre-IND feedback from FDA on CLD-401 — BioWorld
- 9:00 AM · BioWorld
- 8:30 AM · SCMP — Tech8:30 AMChinese chip-equipment maker CFMEE targets US$410 million in Hong Kong IPO — SCMP — Tech
- 7:43 AM · STAT News
- 6:17 AM · Pharmaceutical Technology6:17 AMAviadoBio broadens vMiX gene silencing licence with King’s College London — Pharmaceutical Technology
- 5:32 AM · Pharmaceutical Technology5:32 AMEHA26: BMS touts positive multiple myeloma data for two pipeline candidates — Pharmaceutical Technology
- 5:00 AM · BioPharma Dive5:00 AMA new Westlake-backed biotech takes aim at migraines — BioPharma Dive
- 4:56 AM · Pharmaceutical Technology4:56 AMAltaris to acquire Simulations Plus in $375m all-cash deal — Pharmaceutical Technology
- 4:53 AM · Pharmaceutical Technology4:53 AMZai Lab’s zocilurtatug pelitecan secures EMA orphan drug status — Pharmaceutical Technology